Cas:183673-70-3 tert-butyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate

CAS.NO:183673-70-3

Synonyms:8-Boc-2,4,8-triazaspiro[4.5]decane-1,3-dione;8-Boc-2,4,8-triazaspiro[4,5]decane-1,3-dione;8-tert-butoxycarbonyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione;1-T-BOC-PIPERIDINE-4-SPIRO-5′-HYDANTOIN;tert-butyl 1,3,8-triaza-2,4-dioxo-8-spiro[4.5]decanecarboxylate;8-BOC-2,4,8-TRIAZASPIRO[4.5]DECANE-1,3-DIONE;2,4-Dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester

Molecular Formula:C₁₂H₁₉N₃O₄

Molecular Weight:269.29700

HS Code:2933990090

Physical and Chemical Properties:

Melting point:242-244ºC

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:87.74000

Exact Mass:269.13800

LogP:1.19100

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 8-Boc-2,4,8-triazaspiro[4.5]decane-1,3-dione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 1,3,8-triaza-2,4-dioxo-8-spiro[4.5]decanecarboxylate Use and application,2,4-Dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester technical grade,usp/ep/jp grade.

Related News: Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality. tert-butyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate manufacturer One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. tert-butyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate supplier In order to find answers to these questions, our staff in the development department set about conducting a series of experiments. tert-butyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. tert-butyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate factory The U.K. government previously purchased more than 380 million rapid tests from Innova, to help set up programs capable of screening millions of people per day—in the run-up to offering free COVID-19 testing nationwide at least twice per week.